Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Undisclosed
Deal Size : $7.4 million
Deal Type : Funding
Aqemia Expands Into Small-Molecule RNA Targeting with $7.4M Grant
Details : Through the funding Aqemia aims to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Undisclosed
Deal Size : $7.4 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Cathay Innovation
Deal Size : $38.0 million
Deal Type : Funding
AQEMIA Hits $100M Funding Milestone, Eyes Trials and Global Expansion in UK
Details : Aqemia will use the proceeds to continue to advance its technology platform to transform drug discovery, designing innovative and safe small-molecule for cancers.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Cathay Innovation
Deal Size : $38.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Iktos
Deal Size : Undisclosed
Deal Type : Acquisition
Iktos Acquires Synsight for Protein and RNA-Protein Drug Discovery
Details : Iktos acquires Synsight, a life sciences technology specializing in protein-protein and RNA-protein interactions-targeted drug discovery in many diseases such as cancer and neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 07, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Iktos
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,483.0 million
Deal Type : Licensing Agreement
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Details : Under the collaboration, Sanofi exercised one option to license a new ANKET® (antibody-based NK cell engager therapeutics) platform from Innate, for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $26.6 million
December 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,483.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Acquisition
Mablink Bioscience Enters an Agreement to be Acquired by Lilly
Details : Through the acquisition, Eli lilly expands its portfolio of antibody-drug conjugates for cancer by gaining Mablink’s existing pipeline and proprietary PSARLink™ technology, an innovative hydrophilic linker which holds potential for broadening the the...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
AstraZeneca Scraps Transgene Pact in Blow to Oncolytic Viruses
Details : Under the termination, Transgene will regain the global rights to the intravenous oncolytic virus drug candidate, developed using Transgene’s next-generation viral Invir.IO™ platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Oncode Bridge Fund
Deal Size : Undisclosed
Deal Type : Funding
Oncode Institute and ArgoBio Launch Laigo Bio
Details : The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 02, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Oncode Bridge Fund
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Casdin Capital
Deal Size : $90.0 million
Deal Type : Series A Financing
Mnemo Banks $90M To Tackle Barriers in CAR-T Therapy
Details : The Series A financing will allow the company to accelerate development of the EnfiniT targeting and next generation chimeric antigen receptors (CAR) T cell therapy platform combining the pioneering research from Institut Curie and Memorial Sloan Ketteri...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Casdin Capital
Deal Size : $90.0 million
Deal Type : Series A Financing